CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2014		Jun. 30, 2013
OPERATING ACTIVITIES:
Net income (loss)	$ 7,031		$ (4,508)	[1]
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	29,164		24,025	[1]
Non-cash impairment charges	600		0	[1]
Deferred income tax provision (benefit)	(503)		(400)	[1]
Amortization of debt issuance costs	1,243		1,094	[1]
Non-cash interest expense	3,433		3,232	[1]
Loss on disposal of property and equipment	378		1,831	[1]
Loss/(gain) from increase/(decrease) in fair value of contingent consideration liabilities	(998)		0	[1]
Share-based compensation	8,302		4,764	[1]
Excess tax benefits from stock-based compensation arrangements	(1,164)		(102)	[1]
Changes in assets and liabilities, net of business acquisitions:
Accounts receivable	106		(745)	[1]
Inventories	(17,367)		(19,398)	[1]
Prepaid expenses and other current assets	(2,832)		(1,294)	[1]
Other non-current assets	(1,846)		(368)	[1]
Accounts payable, accrued expenses and other current liabilities	4,848		2,893	[1]
Deferred revenue	188		278	[1]
Other non-current liabilities	(2,952)		(538)	[1]
Net cash provided by operating activities	27,631		10,764	[1]
INVESTING ACTIVITIES:
Purchases of property and equipment	(20,691)		(24,475)	[1]
Sales of property and equipment	0		530	[1]
Cash used for business acquisition, net of cash acquired	(235,000)		(2,830)	[1]
Net cash used in investing activities	(255,691)		(26,775)	[1]
FINANCING ACTIVITIES:
Borrowings under senior credit facility	235,000		20,000	[1]
Payments of Debt Issuance Costs	0		(1,013)	[1]
Principal payments under capital lease obligations	(245)		0	[1]
Proceeds from exercised stock options	8,317		234	[1]
Excess tax benefits from stock-based compensation arrangements	1,164		102	[1]
Net cash provided by financing activities	244,236		19,323	[1]
Effect of exchange rate changes on cash and cash equivalents	370		(1,614)	[1]
Net change in cash and cash equivalents	16,546		1,698	[1]
Cash and cash equivalents at beginning of period	120,614	[1]	96,938	[1]
Cash and cash equivalents at end of period	$ 137,160		$ 98,636	[1]

[1] See Note 1 of these condensed consolidated financial statements for discussion of the impact of the change in accounting for the medical device excise tax.